US 11,236,156 B2Granted

Compositions and methods for targeting activin signaling to treat cancer

AssigneeThe Johns Hopkins University

InventorsFan Pan, Duojia Pan, Drew M. Pardoll, Joseph Barbi, Juan Fu

Life of this patent

Estimating the term…

Abstract

The present invention relates to compositions and methods for treating cancer by targeting the Activin signaling pathway. In certain embodiments, combining Activin blockade with immunomodulation alters regulatory T (Treg) cell-mediated immune regulation and treats cancer.

Claims7

Dependent claims

A method of inhibiting Foxp3+ regulatory T cell (Treg) activity or proliferation in an anti-tumor immune response in a subject comprising administering to the subject an effective amount of a composition comprising an anti-Activin A antibody.

Dependencies are inferred from the claim text.

Facts

Application: 16/077,368Filed 10 Feb 2017 · us provisional application
Priority: 11 Feb 2016
Published: US 2019/0077855 A114 Mar 2019
Granted: 1 Feb 2022
Term ends: Not estimatedThe source records don’t support an estimate.

Classification12 codes

C07K 16/22
Against material from animals or humans: against growth factors ; against growth regulators
A61K 31/7105
Compounds having three or more nucleosides or nucleotides: natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine,…
A61K 38/179
Receptors; Cell surface antigens; Cell surface determinants: for growth factors; for growth regulators
A61K 39/3955
Against materials from animals: against proteinaceous materials, e.g. enzymes, hormones, lymphokines

Family

Application62/293,915Us provisional application · filed 11 Feb 2016
US 2019/0077855 A1Pre-grant publication · published 14 Mar 2019
US 11,236,156 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results